Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

Future of Regenerative Medicine with Kyle Cetrulo of AuxoCell

April 26, 2017 By Cade Hildreth, Founder & President Leave a Comment

I had the honor of interviewing Kyle Cetrulo, CEO of AuxoCell Laboratories. In this interview, we explore the upcoming Future of Regenerative Medicine Congress, as well as future directions for regenerative medicine at large. Enjoy. [Read more…]

Cynata Files for New Patent for Oncology Applications

April 12, 2017 By Cade Hildreth, Founder & President Leave a Comment

• Further patent application filed for oncology applications

• Patents strengthen the Company’s intellectual property and solidifies its focus in the field of oncology

• Patent filing forms a key part of the Company’s strategy to protect its platform

[Read more…]

Cynata Ramping Up Asthma Program

April 4, 2017 By Cade Hildreth, Founder & President Leave a Comment

Late last year, Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), developed compelling data in an asthma model and is now ramping up that program.

In October 2016, Cynata announced it had received convincing data from a proof of concept study of its Cymerus™ iPSC-derived mesenchymal stem cells (MSCs) in an experimental model of asthma. Those initial results demonstrated that Cymerus™ MSCs can exert a powerful effect via improved airway hyper-responsiveness. [Read more…]

Cynata Therapeutics Lands Japanese Giant Fujifilm

March 28, 2017 By Cade Hildreth, Founder & President Leave a Comment

It is not every day that an Aussie minnow lands a deal with a Japanese whale. When Fujifilm took a 9% equity stake in Cynata Therapeutics Ltd (ASX: CYP), it was a major lift for the regenerative medicine company, positioning Cynata to benefit not only from Fujifilm’s resources but also more broadly from current economic strategy within Japan.

Prime Minister of Japan, Shinzō Abe, has committed to building leadership around a new generation of regenerative medicine products involving human cells and tissues and Cynata is now perfectly positioned to take advantage of this in the world’s second largest market for healthcare products. [Read more…]

Dr Paul Wotton appointed as Chairman of the Cynata Board

March 2, 2017 By Cade Hildreth, Founder & President Leave a Comment

Melbourne, Australia; 28 February 2017 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP) is pleased to announce the appointment of existing nonexecutive director Dr Paul Wotton as Chairman of the Board of Directors. With Cynata now transitioning to a clinical stage company, the Board believes that Dr Wotton has the skills, focus and proven track record to help steer the Company effectively through this next stage of growth. Past chairman Dr Stewart Washer will remain on the Board as a non-executive Director. [Read more…]